drugset / Trial / NCT00595049
Pulmonary Artery Remodelling With Bosentan
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to investigate whether bosentan (Tracleer®) affects the wall thickness of the pulmonary arteries in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH related to systemic sclerosis (PAH-SSc). The second purpose is to investigate if bosentan affects the enlargement of small vessels in the lungs in response to natural chemicals in patients with iPAH and PAH-SSc.
Timeline
- Start
- 2006-05-31
- Primary completion
- 2008-12-31
- Completion
- 2010-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosentan | Other / unclassified | 125 mg | — |